Bruno Farmaceutici

What Bruno Farmaceutici does

Bruno Farmaceutici S.p.A. is a privately held Italian pharmaceutical company founded in 1996 in Rome by Dr. Antonio Bruno, who acquired a business unit from Aventis (Lepetit Group). The company develops, produces, and commercializes branded and generic prescription drugs focused on chronic disease treatment, organized across nine therapeutic areas: cardiovascular, pain and inflammation, diabetes and obesity, osteoporosis, insomnia, infectious disease, addiction, dietary supplements, and other products. Its core technology is pharmaceutical formulation — including modified/controlled-release and fixed-dose combinations — anchored by a proprietary iron chemistry (IHAT™) used in the IRONDELTA supplement. Flagship franchises include Deltacortene (prednisone), described as the gold standard solid oral corticosteroid in Italy, and Glucophage (metformin) for type 2 diabetes; the company also markets the first teriparatide biosimilar launched in Italy and combination products such as DIESMIT, COMPUNA, LODICAND, and NEODISET.

The business model is direct pharmaceutical commercialization in Italy. Products are sold through a field sales force of nearly 140 medical-scientific representatives to pharmacies, with most molecules reimbursed by the Italian National Health Service (SSN) under Class A; a smaller set of products, notably MYSIMBA for obesity, is sold directly to patients under Class C at retail prices. The ophthalmic line was added in 2012 through the acquisition of Safilens, and the diabetes franchise was reinforced the same year via the CardioMetabolica line acquired from Merck Serono. The company holds ISO 9001:2015 and UNI/Pdr 125:2022 certifications, maintains a 1,000 sqm HCP training facility ("Il Noceto") in Amelia, and has signaled intent to extend into nutraceuticals through patented dietary supplements. Operations and customers are entirely Italy-based, with no disclosed international revenue.

Name

Bruno Farmaceutici

Legal name

Bruno Farmaceutici S.p.A.

Website

https://bruno.org

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Bruno Farmaceutici is a privately held Italian pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs across nine chronic-disease therapeutic areas, selling primarily through a 140-rep field force to Italian pharmacies and the SSN.

Ownership category

akta.pro rank

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Supply Chain, Others

Revenue model

1. Pharmaceutical Product Sales: Bruno Farmaceutici generates revenue through development, production and commercialization of branded and generic pharmaceutical products. Products are reimbursed by the Italian National Health Service (SSN) or sold through pharmacies to patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Bruno Farmaceutici S.p.A. is an Italian pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs for chronic diseases across multiple therapeutic areas, including cardiovascular, diabetes, osteoporosis, pain and inflammation, insomnia, infectious diseases, addiction, and dietary supplements. The company also operates an ophthalmic products subsidiary (Safilens) producing contact lenses and tear substitutes.

Product overview

Bruno Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1996, market leader in solid oral corticosteroids (DELTACORTENE, BRUCORTEN) and antidiabetic drugs (GLUCOPHAGE). The company operates a multi-category portfolio across 9 therapeutic areas including Pain & Inflammation (FENEXTRA, DURFENTA), Diabetes & Obesity (DIESMIT, MYSIMBA, ACARPHAGE), Osteoporosis (NEODISET, BONASOL, CLODRON, Teriparatide Biosimilar), Cardiovascular (COMPUNA, LODICAND, LOPRESOR, TRINOCARD), Insomnia (ESNOXIBEN), Infectious Disease (CEXIDAL, CEPIMEX), Addiction (CAMPRAL), Dietary Supplements (IRONDELTA, NEULENIC, CITRAK), and Others (CLOMID, SILVERPHAGE). The company also acquired Safilens in 2012, expanding into ophthalmic products. Products are distributed through a sales force of nearly 140 medical representatives targeting primary care physicians and specialists throughout Italy.

Differentiator

Problem solved

Functional benefit

Brands

• Safilens: Ophthalmic products subsidiary specializing in contact lenses and tear substitutes, acquired in 2012.

Products and services

• DELTACORTENE (Prednisone) Market-leading systemic corticosteroid product in solid oral form for anti-inflammatory and immunosuppressive therapy, fully reimbursed by the Italian National Health Service.
• BRUCORTEN (Prednisone lactose-free) Prednisone formulation without lactose for patients with lactose intolerance requiring corticosteroid therapy.
• FENEXTRA (Dexibuprofen) NSAID available in film-coated tablets and granules for oral suspension for pain and inflammation treatment.
• DURFENTA (Fentanyl) Transdermal fentanyl patches for chronic pain management, available in multiple dosage strengths from 12mcg/h to 100mcg/h.
• GLUCOPHAGE (Metformin) First-line antidiabetic medication for type 2 diabetes treatment, available in immediate and prolonged-release formulations.
• DIESMIT (Sitagliptin + Metformin modified-release) Modified-release combination of DPP-4 inhibitor and biguanide for type 2 diabetes, the only modified-release formulation of this combination available in Italy.
• MYSIMBA (Naltrexone + Bupropione) Prolonged-release combination for obesity treatment with dual CNS action reducing appetite and inhibiting food cravings; clinically tested in four 56-week placebo-controlled studies. Class C product not reimbursed by SSN.
• ACARPHAGE (Acarbose) Alpha-glucosidase inhibitor for type 2 diabetes treatment that slows carbohydrate digestion.
• NEODISET (Calcifediol) Vitamin D metabolite (25-hydroxyvitamin D) soft capsules for vitamin D deficiency and osteoporosis treatment, with monthly administration formulation developed in collaboration with Faes Farma.
• BONASOL (Alendronate) Bisphosphonate for osteoporosis treatment, available as oral solution.
• CLODRON (Clodronate) Bisphosphonate for osteoporosis and bone metastases, available in multiple formulations including IM injections with lidocaine.
• Teriparatide Biosimilar First biosimilar of teriparatide in Italy for osteoporosis treatment, recombinant human PTH(1-34) produced in E. coli via DNA recombinant technology, administered via subcutaneous injection once daily.
• COMPUNA (Rosuvastatin + Ezetimibe) Combination of statin and cholesterol absorption inhibitor for hypercholesterolemia treatment and cardiovascular risk reduction, presented in tablets for daily administration.
• LODICAND (Candesartan + Amlodipine) Combination of ARB and calcium channel blocker for essential hypertension replacement therapy.
• LOPRESOR (Metoprolol) Beta-blocker for cardiovascular conditions, available in standard and prolonged-release formulations.
• TRINOCARD (Ramipril + Amlodipine + Atorvastatin) Triple combination of ACE inhibitor, calcium channel blocker, and statin for cardiovascular risk reduction.
• ESNOXIBEN (Eszopiclone) Non-benzodiazepine hypnotic agent for insomnia treatment, available in multiple dosages.
• CEXIDAL (Ciprofloxacin + Fluocinolone) Antibiotic and corticosteroid ear drop combination for infectious-inflammatory ear conditions.
• CEPIMEX (Cefepime) Fourth-generation cephalosporin antibiotic for severe infections, IV formulation.
• CAMPRAL (Acamprosate) Medication for alcohol dependence maintenance treatment, helping prevent relapse.
• IRONDELTA Iron supplement using proprietary IHAT™ (iron hydroxide ferric adipate tartrate) formulation for iron deficiency treatment.
• NEULENIC (Alpha Lipoic Acid) Antioxidant dietary supplement for oxidative stress support.
• CITRAK (Potassium Citrate) Potassium citrate supplement available in multiple formulations for different patient needs.
• CLOMID (Clomiphene) Selective estrogen receptor modulator for anovulation treatment.
• SILVERPHAGE Medical device line for wound care, available as cream gel and spray powder.
• Safilens (Ophthalmic Products) Ophthalmic products company specializing in contact lenses and tear substitutes, acquired in 2012 and operated as a wholly-owned subsidiary with R&D focus on continuous product innovation.

Quantifiable outcome

• Deltacortene is the gold standard corticosteroid reference product
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• SafilenscoreStrategic or Co-development Partner · 1 January 2012Acquired in 2012, Safilens is a leader in the ophthalmic market with highly performing products and technological leadership in contact lenses and tear substitutes. Their R&D center focuses on continuous product innovation. This acquisition expanded Bruno Farmaceutici into the contactology market and provided Safilens access to pharmaceutical R&D capabilities.
• Faes FarmacoreStrategic or Co-development PartnerInternational collaboration with Spanish company Faes Farma for the development and commercialization of calcifediolo formulation for vitamin D deficiency treatment. Faes Farma launched the product in Spain two years prior to Bruno Farmaceutici's launch in Italy. This collaboration allows Bruno Farmaceutici to offer innovative formulations for osteoporosis, malabsorption syndrome, renal osteodystrophy, and corticosteroid-induced bone problems.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Recordati S.p.A. Italian specialty pharma focused on cardiovascular, urology, and rare diseases with strong direct sales in Italy and broader Europe. Closest large-cap peer given parallel Italian specialty pharma model and chronic disease orientation.
• Menarini Group: Privately held Italian pharmaceutical group with diversified portfolio across cardiology, oncology, and gastroenterology plus consumer health. Comparable as an Italian privately held specialty pharma with broad therapeutic area coverage.
• Chiesi Farmaceutici S.p.A. Italian private specialty pharma with respiratory, neonatology, and rare disease focus plus growing cardiovascular presence. Similar private-company structure, Italy HQ, and chronic disease prescription model.
• Zambon S.p.A. Italian family-owned pharma with respiratory, pain, and CNS portfolio and international commercial footprint. Comparable as privately controlled mid-size Italian pharma selling chronic prescription drugs across Europe.
• Angelini Industries (Angelini Pharma): Italian family-owned pharma group with CNS, pain, infectious disease, and consumer health franchises. Closely matches Bruno's diversified therapeutic area approach within a privately controlled Italian company.
• Dompé farmaceutici S.p.A. Italian biopharma with focus on ophthalmology, rare diseases, and primary care, including proprietary R&D. Comparable as mid-sized Italy-based pharma expanding into specialty/biologic categories.
• Italfarmaco S.p.A. Italian private pharma active in cardiovascular, CNS, gynecology, and rare diseases with international subsidiaries. Mirrors Bruno's privately held Italian specialty pharma profile and chronic disease focus.
• Molteni & C. F.lli Alitti S.p.A. Italian specialty pharma focused on pain management, addiction treatment, and rare diseases with strong direct sales in Italy. Direct comparable given overlapping pain, addiction, and chronic disease positioning.

Regional players

• Faes Farma S.A. Spanish specialty pharma with vitamins, OTC, and prescription products; strategic partner of Bruno on calcifediol. Comparable as a mid-size regional pharma with similar therapeutic areas and a co-development relationship with Bruno.

Broad incumbents

• Teva Pharmaceutical Industries Ltd. Global generics leader with broad presence across corticosteroids, cardiovascular, and diabetes categories where Bruno is active. Represents the dominant competitive incumbent in Bruno's largest legacy franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bruno Farmaceutici